Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the fact that, in addition to other modifiable factors linked with progression of multiple sclerosis (MS), dietary factors are also emerging as potentially related to outcomes.
Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the fact that, in addition to other modifiable factors linked with progression of multiple sclerosis (MS), dietary factors are also emerging as potentially related to outcomes.
Transcript
What are modifiable factors that are associated with MS progression?
Well, in addition to the factors that we just discussed, the possibility that alpha-linolenic acid could also be important is quite interesting. People have been looking mostly fish oil. Alpha-linolenic is related to fish oil, but it's different. This omega 3 fatty acid is found in vegetables, in some vegetable oil and walnuts and soybean oil. And the evidence is accumulating that it could be associated with better outcomes in MS.
We are looking at the level of alpha-linolenic acid in blood, in participants in a large trial, the BENEFIT trial, to determine whether they're associated with MS outcomes. And that's a particularly interesting study because the patients have been followed up to 11 years, and they will also have 15 years of follow-up. So we will be able to relate the plasma level of alpha-linolenic acid with long-term outcomes.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More